Superworth

Theriva Biologics EPS TOVX

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$0.69
Latest quarter, Q2 FY26
−$0.07
Fiscal year 2025
−$4.05

Theriva Biologics' earnings per share was −$0.69 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.07.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$4.05n/a
FY2024−$26.66n/a
FY2023−$28.89n/a
FY2022−$32.50n/a
FY2021−$54.75n/a
FY2020−$167.50n/a
FY2019−$245.00n/a
FY2018−$962.50n/a
FY2017−$1472.50n/a
FY2016−$2887.50n/a
FY2015−$5250.00n/a
FY2014−$2887.50n/a
FY2013−$2450.00n/a
FY2012−$3762.50n/a
FY2011−$2625.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.07n/a−$0.69
Q1 FY26−$0.05n/a−$2.55
Q4 FY25−$0.12n/a−$4.05
Q3 FY25−$0.45n/a−$5.53
Q2 FY25−$1.93n/a−$11.89
Q1 FY25−$1.55n/a−$20.68
Q4 FY24−$1.60n/a−$26.66
Q3 FY24−$6.81n/a−$33.10
Q2 FY24−$10.72n/a−$31.14
Q1 FY24−$7.53n/a−$28.92
Q4 FY23−$8.04n/a−$28.89
Q3 FY23−$4.85n/a−$31.10

Against its peers

Companies in Drug Manufacturers - General nearest Theriva Biologics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
TOVXTheriva Biologics−$0.69
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Theriva Biologics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.